The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Phase III trial of azacitidine and gilteritinib in FLT3 mutant AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY discusses the details of a Phase III trial (NCT02752035) of gilteritinib plus azacitidine (aza) versus aza alone in FLT3 mutated acute myeloid leukemia (AML) patients ineligible for standard chemotherapy. Gilteritinib, a FLT3 inhibitor, showed synergy with aza in preclinical investigations. Thus, the trial will randomize approximately 250 patients to gilteritinib plus aza or aza alone, and measure overall survival, remission rates, duration, and safety. Outcomes will also be stratified by age, cytogenetic risk, and FLT3 mutation. Enrollment into the randomization phase has begun. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Eunice Wang, MD, has participated in advisory boards for AbbVie, Astellas, BMS/Celgene, Genentech, Jazz, Kite Pharmaceuticals, Macrogenics, Novartis, Pfizer, PTC Therapeutics, Stemline and Takeda; has fulfilled speaker roles for Stemline, Pfizer and Dava Oncology; and has been a member of data monitoring committees for AbbVie and Rafael Pharmaceuticals.
